Clinical Trial Update: A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic and safety study of moxidectin in children aged 4 to 11 years to identify an optimal dose for treating onchocerciasis. The trial has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Onchocerciasis

Drugs mentioned

• Moxidectin (moxidectin)

Snippet

Sponsor: Medicines Development for Global Health | Conditions: Onchocerciasis | Phase 1 | Status: COMPLETED | Results posted: 2025-01-22